GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Ainos Inc (NAS:AIMD) » Definitions » Debt-to-EBITDA
中文

Ainos (AIMD) Debt-to-EBITDA

: -0.32 (As of Dec. 2023)
View and export this data going back to 1996. Start your Free Trial

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ainos's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $0.04 Mil. Ainos's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $5.92 Mil. Ainos's annualized EBITDA for the quarter that ended in Dec. 2023 was $-18.62 Mil. Ainos's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 was -0.32.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Ainos's Debt-to-EBITDA or its related term are showing as below:

AIMD' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -1.98   Med: -0.68   Max: -0.14
Current: -0.68

During the past 13 years, the highest Debt-to-EBITDA Ratio of Ainos was -0.14. The lowest was -1.98. And the median was -0.68.

AIMD's Debt-to-EBITDA is ranked worse than
100% of 430 companies
in the Medical Devices & Instruments industry
Industry Median: 1.225 vs AIMD: -0.68

Ainos Debt-to-EBITDA Historical Data

The historical data trend for Ainos's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ainos Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.29 -0.67 -1.98 -0.14 -0.68

Ainos Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.35 -0.68 -0.73 -0.78 -0.32

Competitive Comparison

For the Medical Devices subindustry, Ainos's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ainos Debt-to-EBITDA Distribution

For the Medical Devices & Instruments industry and Healthcare sector, Ainos's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Ainos's Debt-to-EBITDA falls into.



Ainos Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Ainos's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.042 + 5.922) / -8.754
=-0.68

Ainos's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.042 + 5.922) / -18.624
=-0.32

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2023) EBITDA data.


Ainos  (NAS:AIMD) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Ainos Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Ainos's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Ainos (AIMD) Business Description

Traded in Other Exchanges
N/A
Address
8880 Rio San Diego Drive, Suite 800, San Diego, CA, USA, 92108
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low dose oral form.
Executives
Meng Lin Sung officer: Chief Financial Officer 8880 RIO SAN DIEGO DRIVE, STE 800, SAN DIEGO CA 92108
Ting-chuan Lee director 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Ainos Inc 10 percent owner 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Pao-sheng Wei director 10F NO 180 SECTION 2, JIANGUO N RD, TAIPEI F5 104071
Chun-hsien Tsai director, officer: Chairman, CEO, CFO 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Chung-jung Tsai director 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Yao-chung Chiang director 5F, 7 ALY 69, LANE 161, TUNHUA S RD., SEC 1, TAIPEI F5 10675
Wen-han Chang director NO 463 FL 4, MING-SHUE ROAD, TAIPEI F5 104046
Lawrence K Lin other: EVP - OPERATIONS 2871 NETTLE CREEK COURT, CHULA VISTA CA 92108
Hui-lan Wu officer: Chief Financial Officer 8880 RIO SAN DIEGO DRIVE, SUITE 800, SAN DIEGO CA 92108
Hsiu-chen Chiu director 9F-1, NO 22, AIGUO E RD, ZHONGZHENG DIST, TAIPEI F5 100408
Chung-yi Tsai director 105 SEQUOIA CT, LOS GATOS CA 95032
Stephen T Chen director 1 GROVE ST, UNIT 812007, WELLESLEY MA 02482-8201
Bernard H Cohen officer: VP, CFO 4134 BUSINESS PARK DRIVE, AMARILLO TX 79110
Dennis Dean Moore director 402 FISH HATCHERY ROAD, HAMILTON MT 59840